The Spanish Society of Medical Oncology (SEOM) has pointed out that, despite the advances achieved in the treatment of lung cancer, "major challenges" still persist in key areas such as prevention, early diagnosis, equality in access to innovations, and research into new therapeutic options.
SEOM reminds that screening programs with low-dose computed tomography have proven their effectiveness by decreasing lung cancer–specific mortality in people at high risk, defined mainly by age and smoking history.
"Its organized implementation with appropriate selection criteria, quality control, and specific care pathways could allow diagnosing a greater number of tumors in stages that may be curable," the scientific society has said.
Coinciding with World Lung Cancer Day, which is commemorated on November 17, SEOM has highlighted some of the recent milestones in tackling this disease. Among them, it stands out for the introduction of immunotherapy in earlier stages of non-small-cell lung cancer.
"Its administration before surgery, in combination with chemotherapy, or through perioperative strategies that include treatment before and after the intervention, has been shown to increase rates of complete pathological response and reduce the risk of relapse in selected patients," it has explained.
The organization has also emphasized that the detection of specific molecular alterations has made it possible to develop targeted therapies against targets involved in the growth and expansion of tumor cells. "To the initial advances in patients with alterations in EGFR, ALK, ROS1, and RET, options against other targets, such as MET, BRAF, HER2, NTRK, and KRAS, have been added," it added.
In this context, it has reiterated that, in advanced disease, precision medicine continues to progress toward combinations and "more effective" drugs, in addition to strategies focused on specific mechanisms of resistance. According to the entity, in patients with lung cancer with EGFR mutations, regimens such as osimertinib combined with chemotherapy or amivantamab combined with lazertinib have expanded therapeutic alternatives in first line.
On the other hand, SEOM has indicated that small cell lung cancer, defined by its marked aggressiveness, is also recording significant advances. In this regard, it has pointed out that the addition of immunotherapy to chemotherapy has managed to improve survival in patients with extensive disease. “More recently, the development of bispecific antibodies capable of activating T lymphocytes against tumor cells has opened up a new therapeutic path,” it added.
The scientific society insists that these progress must be accompanied by policies that guarantee effective prevention, early detection, and equitable access to innovation for all patients with lung cancer.